
PBH Stock Forecast & Price Target
PBH Analyst Ratings
Bulls say
Prestige Consumer Healthcare is anticipated to experience significant growth, with an increased EBITDA estimate for 2026 and 2027 projected to rise by approximately $15 million, driven by heightened sales growth. The company is expected to see an acceleration in organic volume growth rate for specialty foods in the latter half of 2025, supported by numerous product launches, including one of its largest initiatives to date. Additionally, the firm is likely to benefit from improved free cash flow and enhanced EBITDA growth as it exits a prolonged capital expenditure cycle, while U.S. consumer spending is also expected to strengthen, further contributing to positive financial outcomes.
Bears say
Prestige Consumer Healthcare faces a negative outlook due to anticipated lower-than-expected revenue growth and potential EBITDA margin compression driven by persistent high input costs. The company's reliance on North America for approximately 85% of its revenue exposes it to risks associated with a weaker operating environment and declining performance from key customers. Additionally, the expectation of divesting non-core assets in the near future could lead to deleveraging challenges and further financial strain.
This aggregate rating is based on analysts' research of Prestige Brands Holdings and is not a guaranteed prediction by Public.com or investment advice.
PBH Analyst Forecast & Price Prediction
Start investing in PBH
Order type
Buy in
Order amount
Est. shares
0 shares